18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases
Brain Metastases
Conditions: official terms
Brain Neoplasms - Neoplasm Metastasis
Conditions: Keywords
18F-Fluorocholine (18F-FCho), Pet Scan, MRI, 13-199
Study Type
Study Phase
Study Design
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Name: 18F-FCH PET Scan
Type: Procedure
Overall Status
The main purpose of this study is to determine the distribution of 18F Fluorocholine (18F-FCH) in the brain which can help distinguishing radiation-induced scarring from tumor regrowth. In addition, the study will measure levels of 18F-FCH in the blood and (if applicable) in the brain lesion tissue that is removed as part of the planned brain surgery.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 21 Years
Gender: Both
Criteria: Inclusion Criteria:

- Patient and/or guardian is able to provide written informed consent prior to study registration

- Age ≥ 21 years old

- Evolving brain lesions post SRS requiring neurosurgical resection (whether for symptomatic control or to establish pathology)

Exclusion Criteria:

- Inability to undergo a MRI or PET scan (e.g., claustrophobia or metal implant)

- Pregnant or nursing female

- Unable to cooperate for PET/CT
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Status: Recruiting
Contact: Kathryn Beal, MD - 212-639-5159
Start Date
January 2014
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page